New updates have been reported about Juniper Biosciences.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Juniper Biosciences has established a Scientific Advisory Board (SAB) and named Jason S. Lewis, Ph.D., a leading figure in molecular imaging and radiochemistry, as its inaugural chair, positioning the company to sharpen scientific and strategic oversight of its precision oncology programs. The board’s mandate is to guide the development of Juniper’s radiopharmaceutical portfolio, with immediate focus on its lead asset JBS-003, an 18F-fluoromisonidazole hypoxia tracer now in Phase 3 trials for HPV-positive oropharyngeal carcinoma.
CEO Alex Agnoletto said the SAB is being built to ensure Juniper’s clinical programs are scientifically rigorous and operationally efficient, supporting the company’s ambition to commercialize precision diagnostic and therapeutic agents across multiple indications. Dr. Lewis, who holds senior leadership roles at Memorial Sloan Kettering Cancer Center and has more than 380 peer-reviewed publications, will help Juniper navigate complex manufacturing, regulatory pathways, and clinical utility considerations, with Memorial Sloan Kettering and Dr. Lewis both holding financial interests in the company, underscoring a deeper institutional alignment.